Close Menu

NEW YORK – Mutations in the estrogen receptor alpha-coding gene ESR1 appear to occur in a small subset of primary breast cancer tumors, potentially providing a window into cases with poorer-than-usual responses to adjuvant, endocrine-based treatments.

Several prior studies suggest activating mutations in ESR1 can contribute to treatment resistance in metastatic breast cancer cases, explained Malin Dahlgren, a doctoral student in Lao Saal's oncology and pathology lab at Lund University.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.